ACM
MNTA

Atika Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Atika Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-95,000
Closed -$2.5M – 106
2018
Q3 		$2.5M Buy
95,000
+6,000
+7% +$162K 0.45% 74
2018
Q2 		$1.82M Buy
+89,000
New +$1.91M 0.35% 77

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Atika Capital Management's MNTA Position: Q4 2018 in Review

Atika Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2018, closing a stake of 95,000 shares — an estimated $2.5M sold.

Atika Capital Management first reported a position in MNTA in Q2 2018 and held it in 2 quarters. The position peaked at $2.5M in Q3 2018. 158 funds tracked by Wall St. Rank hold MNTA as of Q4 2018.

  • Atika Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Atika Capital Management sold 95,000 Momenta Pharmaceuticals, Inc. shares in Q4 2018, an estimated $2.5M.
  • Atika Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • Atika Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $2.5M in Q3 2018.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2018.

Based on Atika Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.